India, Aug. 20 -- NATCO Pharma Ltd has launched Bosentan Tablets for Oral Suspension (32 mg), a generic version of Tracleer® by Actelion Pharmaceuticals, in the US market. The product will be marketed through NATCO's partner Lupin Ltd.
NATCO, holding first-to-file status, will enjoy 180 days of marketing exclusivity. The tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients (3 years and older) with idiopathic or congenital PAH to improve pulmonary vascular resistance and exercise ability.
According to industry data, Bosentan TFOS (32 mg) recorded sales of around USD 10 million in the US for the 12 months ending June 2025.
Published by HT Digital Content Services with permission from Di...